All In Biotech

NDA 213433 · Sun Pharm

Winlevi

Clascoterone · Topical · Androgen Receptor Inhibitor

Novel

Last checked: Nov 19, 2026Latest source record: Mar 18, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Aug 26, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

24

7 Phase 3, 4 recruiting

FAERS reports

1,419

75 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 2, 2025.

WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. ( 1 )

Mechanism: Clascoterone is an androgen receptor inhibitor. The mechanism of action of WINLEVI cream for the topical treatment of acne vulgaris is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 26, 2020 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • WINLEVI · CLASCOTERONE 1% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clascoterone" as an intervention, any sponsor and status, largest first.

All 24 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product storage error333
  • product physical consistency issue329
  • product use complaint286
  • product dose omission issue184
  • product use issue153
  • drug ineffective146
  • therapy cessation86
  • poor quality product administered84
  • product physical issue78
  • condition aggravated76
  • product quality issue67
  • acne46

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20214
2022500
2023210
2024422
2025269
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Winlevi (Clascoterone)

2024 spending

$1.1M

Beneficiaries

809

1,883 claims

Per beneficiary

$1,385

$9.64 per unit

View as table
YearSpending
2020$0
2021$21,338
2022$514,981
2023$880,218
2024$1,120,073

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Sun Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.